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Antimicrobial resistance: a global response*
Richard D. Smith1 & Joanna Coast2
Abstract Resistance to antimicrobial therapies reduces the effectiveness of these drugs, leading to increased morbidity, mortality, and
health care expenditure. Because globalization increases the vulnerability of any country to diseases occurring in other countries,
resistance presents a major threat to global public health, and no country acting on its own can adequately protect the health of its
population against it. International collective action is therefore essential. Nevertheless, responsibility for health remains predominantly
national. Consequently, there is a potentially significant disparity between the problems and solutions related to antimicrobial
resistance and the institutions and mechanisms that are available to deal with them.
This paper considers the capacity of national and international institutions and mechanisms to generate a collective response to
antimicrobial resistance. Strategies for containing resistance are outlined, with particular reference to globally coordinated activities of
countries. The adequacy of national and international responses to resistance is assessed, and the actions that international bodies
could take to solve difficulties associated with present responses are highlighted. Approaches are suggested for securing international
collective action for the containment of antimicrobial resistance.
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Introduction
The ability of microorganisms to become resistant to the major
therapies used against them has long been recognized and is
becoming increasingly apparent (1, 2). Resistance rates for many
isolates are rising but are highly variable. For example, the
proportion of isolates of Staphylcoccus aureus resistant tomethicillin
increased from close to zero 10–15 years ago to approximately
70% in Japan and the Republic of Korea, 40% in Belgium, 30%
in the UnitedKingdom, and 28% in the USA by 1998 (1). Recent
rates of resistance to Streptococcus pneumoniae were less than 2% in
Belgium, Italy, and Finland, but 7% inGermany, 9.5% in Iceland,
25% in Romania, 44% in Spain and 58% in Hungary (3).
Increasing antimicrobial resistance (AMR) presents a
major threat to public health because it reduces the
effectiveness of antimicrobial treatment, leading to increased
morbidity, mortality, and health care expenditure (4). For
example, the mortality rate in outbreaks involving resistant
strains of Salmonella spp. was found to be 3.4%, whereas it was
only 0.2% in those involving sensitive strains (5). In 1995 the
cost of containing an outbreak of infection caused by
methicillin-resistant S. aureus in a district general hospital in
theUnitedKingdomwas estimated to exceedUS$ 560 000 (6),
while the annual health care cost associated with the treatment
of resistant infections in the USA was estimated at over
US$ 4 billion (7), an amount recently revised to more than
US$ 7 billion (8). AMR is the cause of professional, govern-
mental, and public concern (9–12) and has been classified as a
national security risk in the USA (13, 14).
The rate of development of AMR is accelerated by the
use and misuse of antimicrobials (15). The factors responsible
include over-the-counter availability of antimicrobials without
professional controls (16), the use of drugs of low potency and
effectiveness as a result of poor manufacture (17) or
counterfeiting (18), and the availability of drugs from roadside
stalls and hawkers who have little or no knowledge of dosage
regimens, indications or contraindications (19). Containment
of AMR thus requires a range of strategies.
AMR is a global problem (20). Globalization increases the
vulnerability of countries to imported diseases, and infectious
diseases travel faster and further than ever before (21, 22).
During the 1990s, for example, a resistant Pneumococcus sp. first
identified in Spain was rapidly found in Argentina, Brazil, Chile,
China (Province of Taiwan), Columbia, Malaysia, Mexico, the
Philippines, Republic of Korea, South Africa, Thailand, USA,
and Uruguay (23). No country acting on its own can adequately
protect the health of its population against AMR. International
collective action is essential, yet responsibility for health remains
predominantly national (24). Consequently, there is a potentially
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significant disparity between the problems and solutions
associated with AMR and the institutions and mechanisms
available to deal with them (25).
The present paper discusses the capacity of national and
international institutions and mechanisms to generate a
collective response to AMR. Strategies are outlined for
containing such resistance, with particular reference to globally
coordinated activities. The adequacy of existing national and
international responses is assessed; actions that international
bodies could take in order to tackle some difficulties are
examined; and approaches are suggested for securing interna-
tional collective action for the containment of AMR.
Strategies for containment of antimicrobial
resistance: global collective action
The eradication of AMR is neither a realistic nor a desirable
goal. To eradicate resistance would require a significant
reduction in the use of antimicrobials and in the benefits
obtained from them. The aim should therefore be to contain
resistance, to optimize the balance between the effective use of
antimicrobials against infection, thus reducing morbidity,
mortality and further spread of infection now, and the
emergence and spread of resistance to the drugs leading to
increased morbidity and mortality in the future.
The containment of resistance may be defined as a public
good since it is impossible to exclude people from benefiting
from containment, and one person who benefits does not stop
another from benefiting, i.e. there is non-rivalry in consumption
(26). These characteristics mean that the containment of
resistance is bound to be suboptimal in the absence of
interventions because some people rely on containment
provided by others. It is important to note that the containment
of AMR has these characteristics at both the global and national
levels. Containment is therefore a global public good (26).
There are many strategies for containing AMR and these
can be pursued at different levels. An illustrative list is provided
in Table 1. Some strategies aim to avoid the emergence of new
resistance, whereas others seek to prevent the transmission of
existing resistance (27). Clearly, transmission can only occur
once resistance has emerged. The primary goal is therefore to
avoid the emergence of resistance (28).
Table 1 also indicates the level at which intervention is
required to optimize AMR containment. Many strategies are
best provided at the national level because of the diverse
contexts in which policies have to be implemented and the
variation in resistance to, and therefore effectiveness of,
infective agents, even across relatively small areas and with the
passage of time. For some strategies, however, AMR contain-
ment can clearly be achieved more efficiently by international
collective action than by nations acting individually.
The dominant strategies nationally, regionally and
globally are as follows: surveillance of AMR and the tracking
of antimicrobial consumption; use of mechanisms to en-
courage research on and development of new antimicrobials
and alternative treatments; and adoption of measures ensuring
appropriate and rational use of existing antimicrobials (15).
Surveillance
Surveillance is fundamental to any strategy for AMR contain-
ment, providing the data required to locate an AMR problem,
monitor its growth, transmission and direction of travel, and
determine the impact of interventions intended to contain
it (15). Collective action is required in order to produce
effective surveillance systems because: the barriers to estab-
lishing surveillance systems are high, particularly for poorer
nations, given the large initial investment required; surveillance
produces benefits for other countries which an individual
nation does not account for in deciding whether to invest in a
surveillance system; and a global system requires comparable
data of adequate quality.
Although there have been some developments globally,
e.g. surveillance of multidrug-resistant tuberculosis (MDR-
TB) (29), surveillance is largely undertaken in a piecemeal
fashion. Few countries have well-established national net-
works; many microbiology laboratory facilities and informa-
tion networks require strengthening; and there are no
international regulations enforcing comparable collection,
classification, or reporting of data. There is thus a lack of
information-sharing and an incentive to obtain and use
information generated by and for other countries without
incurring the cost of reciprocation.
Evidence from other areas suggests that even the
creation of a legal duty does not ensure compliance, but rather
that compliance depends on the availability of adequate
resources (30, 31). Such resources are often lacking in poorer
countries or subject to more extreme ‘‘opportunity costs’’ in
terms of benefits forgone arising from the alternative use of
resources for tackling health problems directly (32). The cost
of establishing surveillance systems varies with the infra-
structures and surveillance facilities that are available. Initial
work on the feasibility of establishing surveillance systems
globally could therefore be based on experience already gained
in national surveillance to determine the level of resources
required, the extent to which these are already met in particular
countries, and the resources needed to set up surveillance
systems at particular levels in different countries.
Research and development on new antimicrobial
and other therapies
Although knowledge is a classic public good, in practice the
enormous cost of research and development means that
patents are used to transform it into a private good, i.e. one
from which people can be excluded, thus providing the
incentive for private sector investment. A key element in the
future development of therapies that have lower rates of AMR,
or alternatives to antimicrobial therapy, is thus to encourage
research and development in the private sector.
The need for collective action in securing private sector
investment primarily arises because of conflict between
strategies for controlling the use of antimicrobials as a means
of containing resistance and those formaintaining research and
development on new antimicrobials. This is most obvious
where strategies seek to restrict or reduce antimicrobial
consumption, i.e. most strategies for containing the emergence
of resistance (Table 1), since this threatens profitability, a
function of volume and price, indicating that research and
development are not likely to be undertaken. These problems
could be tackled through compensating policies that might
involve allowing or subsidizing increases in price to offset
reduced sales volumes, considering orphan drug status for
some products, or conducting advance purchase deals in order
to secure an incentive for investment (33). Alternatively, AMR
may present a market potential: by reducing the effectiveness
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Table 1. Characteristics of strategies for containing emergence and transmission of resistancea
Level of interventionGeneral strategies appli-
cable to containment
of both emergence and
Local National Regional Global
transmission of resistance
1. Surveillance Required at all levels in order to obtain an accurate picture of emerging resistances and the rate of transmission of new
resistances, and to identify the impact of interventions designed to contain antimicrobial resistance in particular contexts
2. Financial incentives
or disincentives
Could be used at all levels in conjunction with many other policies as a mechanism for improving uptake of or compliance
with any intervention. Would include such mechanisms as financial benefits, environmental taxes and use of permit systems
Strategies for containing emergence of resistance
1. Education of pro-
fessionals on appropriate
clinical indications
On specific problematic mi-
croorganisms in local areas
On issues most relevant to
general national conditions
On general principles through
regional organizations and
the Internet
On general principles through
global organizations and
the Internet
2. Education of patients
on inappropriate use and
importance of compliance
with instructions on
taking antimicrobials
Local campaigns and ad hoc
education by health profes-
sionals at time of patient
consultation
By providing national infor-
mation campaigns, e.g. as
recently conducted in the
United Kingdom (leaflets,
magazine ads, etc)
On general principles through
regional organizations and
the Internet
On general principles through
global organizations and the
Internet
3. Rapid diagnosis of
bacterial infections
By improving local facilities By providing infrastructure
for improved local facilities
Through provision of aid
to countries whose
infrastructure is lacking
Through provision of aid
to countries whose
infrastructure is lacking
4. Control of sensitivity
data related to prescribers
From local facilities By providing infrastructure
for improved local facilities
5. Antimicrobial policies Developed by local facilities
taking account of specific
local conditions
Developed by national medical
associations taking account
of general national conditions
6. Restriction of drug
availability
Taking account of specific
local issues BUT may
potentially be considered
unacceptable on grounds
of geographical equity
Developed by national policy-
makers taking account of
general national conditions
7. Antimicrobial cycling Carried out at local level,
taking account of prevailing
local conditions
8. Regulation of use of
antimicrobials in agriculture
Developed by national policy-
makers taking account of
general national conditions
Through regional agreements,
e.g. through the European
Union
Through international
agreements, e.g. through
WHO
9. Choosing optimal agent,
dose and dosage frequency
for different infections
Carried out at patient level,
taking account of prevailing
local conditions and particular
patient characteristics
10. Removal of potential
septic foci/prostheses
Carried out at patient level
11. Use of drug
combinations
At local/patient level, taking
account of prevailing local
conditions and particular
patient characteristics
12. Using antiseptics as an
alternative to antimicrobials
At patient level, taking
account of prevailing local
conditions and particular
patient characteristics
Guidelines suggesting use of
alternative agents could be
produced at national level
13. Using cranberry juice as
an alternative to antibiotics
for urinary tract infection
At patient level, taking
account of prevailing local
conditions and particular
patient characteristics
Guidelines suggesting use of
alternative agents could be
produced at national level
Table 1, continued on p. 129
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of existing drugs it may provide an expanding market for new
effective drugs. In this case, AMR may itself provide an
incentive for companies to invest in antimicrobials, although in
practice there has been little recent development of new
antimicrobials to support this.
International differences in pricing structures, patent
laws, intellectual property rights legislation, and drug registra-
tion and licensing mean that companies may engage in
differential research and development policies. For example,
they may target the development of drugs that focus on the
problems of wealthier countries (22, 30). Such differentiation
implies that successful policies for containing AMR in one
country may simply shift the problem to another.
Collective action on a number of fronts is therefore
necessary, including the reform of international patent laws
and the coordination of licensing and regulatory requirements
(24). It also includes directly undertaking or sponsoring
research and development. There are precedents for interna-
tional support of research and development on diseases posing
significant international concern. For example, with the
support of WHO and the World Bank, the Multilateral
Initiative on Malaria coordinates research on antimalarial
(Table 1, continued)
Level of interventionGeneral strategies appli-
cable to containment
of both emergence and
Local National Regional Global
transmission of resistance
14. Using probiotics as
an alternative to
antimicrobials
At patient level, taking
account of prevailing local
conditions and particular
patient characteristics
Guidelines suggesting use of
alternative agents could be
produced at national level
15. Increasing vaccination
in order to increase
immune competence
Operation of national
policies at local level
National policy development
concerning vaccination,
including both guidance
and financial incentives
Through provision of aid in
order to improve vaccination
levels in countries that
cannot afford vaccination
programmes
Through provision of aid in
order to improve vaccination
levels in countries that
cannot afford vaccination
programmes
16. Improving nutrition in
order to increase immune
competence
Local policy development
focusing on particular
communities
National policy development Through provision of aid to
countries with poor nutrition
Through provision of aid to
countries with poor nutrition
17. Minimizing time patient
is immunocompromised
At patient level
Strategies for containing transmission of resistance
1. More rapid diagnostic
techniques
By improving local facilities By providing infrastructure
for improved local facilities
Through provision of aid to
countries whose infrastructure
is lacking
Through provision of aid to
countries whose infrastructure
is lacking
2. Screening of patients/
staff
E.g. on admission to
hospital
Guidelines on screening could
be produced at national level
3. Use of antimicrobials
to reduce infectivity
In particular patients
4. Isolation Of particular patients Guidelines on isolation could
be produced at national level
5. Handwashing In particular institutional
settings
Guidelines on handwashing
could be produced at
national level
6. Improvements in bed
spacing
In particular institutional
settings
Guidelines on bed spacing
could be produced at
national level
7. Improving immunity
by vaccination in order
to reduce susceptibility
to infection
Operation of national policies
at local level
National policy development
on vaccination, including
both guidance and financial
incentives
Through provision of aid in
order to improve vaccination
levels in countries that
cannot afford vaccination
programmes
Through provision of aid in
order to improve vaccination
levels in countries that
cannot afford vaccination
programmes
8. Improving nutrition in
order to reduce susceptibility
to infection
Local policy development
focusing on particular
communities
National policy development Through provision of aid to
countries with poor nutrition
Through provision of aid to
countries with poor nutrition
a Heavily shaded cell = a strategy inappropriate at a particular level. Lightly shaded cell = an intervention primarily at the local or national level but which may need
international aid in order to provide the intervention in some countries.
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products (34–37) and a similar approach should be considered
also for research into new antimicrobials.
Encouraging appropriate and rational use
of antimicrobials
Policies and regulations that encourage more appropriate and
rational use of antimicrobials are key long-term interventions
for the containment of AMR (15, 26). However, the effects of
many national policies may not be optimal from a global
perspective if countries fail to take account of the cross-
border effects of their actions. Since the sum of actions by
individual nations does not equal the optimal global response,
some element of collective action is therefore required. Even
at the national level there are formidable problems in
regulating the use of antimicrobials because of the hetero-
geneity of patients (the monitoring of clinical practice
involves potentially high transaction costs associated with
bureaucracy) and the potential conflict with clinical freedom
(38). There is therefore a place for the use of financial
incentives and disincentives at the global level, as well as for
international legislation that encourages the optimal use of
antimicrobials.
Little action is taking place internationally to tackle drug
usage. For example, current talks between the European
Union, Japan and the USA on the harmonization of
pharmaceutical regulatory systems are somewhat limited, and
the extent to which AMR is being specifically discussed is
unclear. The potential for financial incentives and disincentives
at this level has received little consideration. This is also true of
the role of international legislation on enforcing strategies,
covering, for example, intellectual property rights, the
requirement for AMR data in the pre-approval evaluation of
drugs, the use of subtherapeutic doses as growth promoters in
animals, the labelling of drugs, and prescription requirements.
However, work has been carried out to develop international
standard treatment guidelines, which are similar, for example,
to current WHO AMR surveillance standards (39), WHO
guidelines for the treatment of MDR-TB (40), and WHO
protocols for the detection of drug-resistant malaria (41). Such
guidelines are important global public goods, if accessible,
adaptable to local circumstances and, crucially, backed up with
access to technology and infrastructure and, potentially, some
form of incentive mechanism.
Securing global collective action: role
of international bodies
Global collective action is clearly necessary to secure
internationally compatible surveillance systems, develop new
therapies, and ensure more rational use of antimicrobials. In
securing collective action it is essential to consider the
economic and legal dimensions, which are interrelated.
Economic dimension
Successful collective action requires the participants to
perceive a net benefit, often in economic terms (42). This
simple requirement is often overlooked. For example, whereas
reductions in the use of chlorofluorocarbons were achieved
relatively quickly and easily, reducing carbon emissions has
been more difficult, largely because of the respective benefits
and costs perceived by the USA.
Also, the imbalance of wealth between countries
exacerbates the potential for ‘‘free riding’’, since the marginal
opportunity cost of using a resource is higher in poor than
wealthy nations, creating a disparity between national priorities
and the place of AMR containment within them; and even if
countries could be persuaded to become involved in strategies
such as surveillance, many lack the financial, technical or
physical infrastructure necessary to do so (43, 44).
Legal dimension
A global response to AMR may be achieved through
harmonization of individual national mechanisms, legislation
and strategies, or through the construction of new international
mechanisms, legislation, and bodies. WHO, the World Bank
and the United Nations are the international organizations
most qualified to take major roles in tackling these issues.
Indeed, WHO has already begun to do so, with the
development of its global strategy to contain AMR (15).
However, this strategy follows the historical preference of
WHO and other international bodies for operating through
recommendations and guidelines, relying largely on ad hoc
harmonization of individual national mechanisms, legislation
and strategies, rather than on formal international legislation.
Unfortunately, evidence suggests that this may be inadequate
to contain AMR in the long run (24, 45).
It may be more productive to appeal directly to
international legislative frameworks, with legally binding sup-
port from wealthy nations and technical assistance and support
in specific areas such as information technology. For example,
international legal frameworks could cover the availability of
specific drugs and labelling and licensing requirements, and
would be built on agreed international legislation.
Combining the economic and legal dimensions
In order to achieve an integrated strategy encompassing global
surveillance, research and development, and the more
appropriate use of therapies, a hypothetical global government
would ideally establish a legal imperative to comply with
strategies and develop structures enabling the transfer of
resources from wealthy to poor nations so that compliance
could occur. In the absence of a global government,
international agencies should undertake this task in order to
secure international collective action.
Funding is critical. So-called ‘‘soft law’’, e.g. recommen-
dations, framework conventions, and agreements, works only
if countries are both willing and able to comply. For many
countries the ability to comply is lacking. For example,
surveillance requires procedures for collecting and transport-
ing samples, the existence of laboratory facilities, the ability to
report findings, and themonitoring of procedures and findings
in diverse settings. Similarly, rational drug use requires a public
health infrastructure and finance sufficient for the purchase
and dissemination of good quality drugs, as well as othermeans
of combating AMR, such as vaccination and education. This is
feasible, for example, in the European Union and North
America, but countries with comparatively limited resources
are unlikely to be able to sustain such complex systems, with
the result that the problem posed by AMR increases.
Lessons on this matter may be learnt from environ-
mental law and economics. For example, the United Nations
Convention on Biodiversity specifies the financial and
technical assistance required by developing countries from
130 Bulletin of the World Health Organization 2002, 80 (2)
Special Theme – Commission on Macroeconomics and Health
developed countries in order to reduce unsustainable devel-
opment, and establishes institutional machinery for overseeing
the implementation (46, 47). A similar arrangement, whereby
developed countries provide financial and technical assistance
to developing countries or are subject to differential duties, is
found within the framework protocols relating to ozone
depletion and global warming (e.g. the Montreal and Kyoto
Protocols). Such bargains could also be envisaged in relation to
global strategies for the containment of AMR.
It is also important to consider the global funding of access
goods, i.e. private goods required to facilitate access to the public
good. For example, in order to benefit from the public good of
clean water a household has to be connected to the
infrastructure. Access goods, while not global public goods
in themselves, may be treated as such to the extent that the
international coordination of their finance and provisionwould
lead to a more optimal outcome than if each country acted
independently (48). They may therefore be considered to be as
important as the global public good itself, for without the
goods to enable the mechanisms to be utilized or to allow the
benefits to be accessed the global public good of AMR
containment would be difficult, if not impossible, to achieve.
A significant benefit of the concept of global public
goods therefore lies in establishing the impact of a given
country’s non-concordance with the rest of the world
community. These other nations can then be persuaded of
the rationality of ensuring that the country is assisted with
finance for and/or the provision of the strategy in question. To
this extent, international support to strengthen national health
provider systems may be seen as an important input to the
containment of AMR.
Conclusion
A global approach to containment
The global nature of AMR calls for a global response. The
following key activities should be undertaken by international
bodies in order to encourage and promote international
collective action.
Raising the profile and priority of AMR in countries. In
order to secure international cooperation it is necessary to
obtain national recognition of the problem that AMR presents,
the interdependence of countries, and the impact and
responsibility that each country has in relation to global health.
This is a prerequisite for effective global collective action.
Establishment and maintenance of global AMR
surveillance data to which countries contribute and have
access. An important first step is the specification and
coordination of international standards in laboratory suscept-
ibility testing techniques.
Promoting standardization of research methods, coordi-
nating research activities and disseminating information.
International agencies could act as repositories for information
from countries on current research projects and on the
implementation and evaluation of strategies for tackling AMR.
They could also assist in maintaining communication channels
so as to reduce the potential for the ‘‘prisoner’s dilemma’’ (lack
of communication and information about each participant’s
actions, and lack of enforcement mechanisms, impeding co-
operation) arising in communications between countries.
The containment of AMR is a complex process requiring
action ranging from the local to the global level. The greatest
problems associated with AMR undoubtedly remain to be
seen. It is necessary to persuade decision-makers at the national
and international levels of the importance of AMR relative to
other pressing health and non-health priorities. Only if
adequate strategies of collective action are implemented soon
is it likely that high future morbidity and mortality attributable
to AMR can be averted in all countries. n
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Re´sume´
Re´sistance aux antimicrobiens : riposte mondiale
La re´sistance aux traitements antimicrobiens re´duit leur efficacite´ et
entraıˆne une augmentation de la morbidite´, de la mortalite´ et des
de´penses de sante´. Comme la mondialisation rend les pays plus
vulne´rables aux maladies qui surviennent dans d’autres pays, la
re´sistance aux antimicrobiens repre´sente partout une grave
menace pour la sante´ publique et aucun pays ne peut a` lui seul
prote´ger la sante´ de sa population contre ce risque. Une action
collective internationale est donc indispensable. Mais, comme la
responsabilite´ en matie`re de sante´ publique incombe presque
toujours aux autorite´s nationales, il existe une disparite´
potentiellement importante entre les proble`mes lie´s a` la re´sistance
aux antimicrobiens – et leurs solutions – et les institutions et
me´canismes disponibles pour y faire face.
Le pre´sent article examine la capacite´ des institutions et
me´canismes nationaux et internationaux a` organiser une riposte
collective a` la re´sistance aux antimicrobiens. Il de´crit des
strate´gies d’endiguement, en citant particulie`rement les activite´s
des pays coordonne´es au niveau mondial, e´value l’ade´quation
des ripostes nationales et internationales a` la re´sistance et
souligne les mesures qui pourraient eˆtre prises par les
organismes internationaux pour re´soudre les difficulte´s asso-
cie´es aux me´canismes actuels. Diverses approches sont
propose´es pour assurer que des mesures collectives puissent
eˆtre prises au niveau international dans le but d’endiguer la
re´sistance aux antimicrobiens.
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Resumen
Resistencia a los antimicrobianos: una respuesta mundial
La resistencia a los tratamientos conantimicrobianos reduce laeficacia
de estos medicamentos y da lugar a un aumento de la morbilidad, de la
mortalidad y del gasto sanitario. Puesto que la globalizacio´n aumenta
la vulnerabilidad de cualquier paı´s a enfermedades que se dan en otros
paı´ses, esa resistencia supone una grave amenaza para la salud
pu´blica mundial, y ningu´n paı´s que actu´e por sı´ solo podra´ proteger
adecuadamente contra ella la salud de su poblacio´n. Ası´ pues, la
accio´n colectiva internacional es fundamental. No obstante, la
responsabilidad de preservar la salud sigue incumbiendo ante todo a
las autoridades nacionales. En consecuencia, se advierte una
divergencia potencialmente importante entre los problemas y
soluciones relacionados con la resistencia a los antimicrobianos y
las instituciones y los mecanismos disponibles para abordarlos.
En este artı´culo se analiza la capacidad de las instituciones y
los mecanismos nacionales e internacionales para articular una
respuesta colectiva a la resistencia a los antimicrobianos. Se
esbozan las estrategias orientadas a contenerla, y se hace especial
referencia a las actividades de los paı´ses coordinadas a nivel
mundial. Se evalu´a la idoneidad de las respuestas nacionales e
internacionales a esa resistencia, y se ponen de relieve las medidas
que los o´rganos internacionales podrı´an adoptar para resolver las
dificultades que plantean las actuales respuestas. Se proponen
diversas alternativas para asegurar que se emprenda una accio´n
colectiva internacional encaminada a frenar la resistencia a los
antimicrobianos.
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